Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

(Reuters) -Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...